September 13, 2011
VBL Therapeutics to Present at the UBS Global Life Sciences Conference

FOR IMMEDIATE RELEASE

Media Contact:

 Dan Budwick, Pure Communications

973-271-6085

 VBL Therapeutics to Present at the UBS Global Life Sciences Conference

 

TEL AVIV, Israel, September 13, 2011 – VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced that Dror Harats, M.D., chief executive officer of VBL, is scheduled to present at the UBS Global Life Sciences Conference on Tuesday, September 20, 2011 at 10:30 a.m. EDT at the Grand Hyatt New York.

 

Dr. Harats is expected to discuss the company’s business strategy, and preclinical and clinical progress with VBL’s innovative portfolio of first-in-class treatments for immune-inflammatory diseases and cancer. Dr. Harats will also outline the company’s goals to advance the development of VB-201, which is currently in Phase 2 clinical trials in patients with psoriasis and patients with elevated hsCRP levels, as well as VB-111, which is in Phase 2 clinical trials in patients with thyroid cancer and glioblastoma.

 

About VBL Therapeutics

 

VBL Therapeutics is an innovative, clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer. VBL has pioneered the Lecinoxoid class of oral anti-inflammatory agents. VB-201 is the company’s lead candidate from this program, currently in Phase 2 clinical development in patients with psoriasis and patients with elevated hsCRP levels. In addition, VBL has a proprietary Vascular Targeting System (VTS™) technology platform that has yielded VB-111, a dual-action, anti-angiogenic and vascular disruptive agent (VDA) for cancer, which is currently in Phase 2 clinical trials for thyroid cancer and glioblastoma. The company is based in Tel Aviv, Israel. VBL has 70 granted patents and more than 110 patents pending. For more information on the company, please visit www.vblrx.com.